There are no cures of AD, but a variety of treatment options exist, most notably the use of cholinesterase inhibitors and other acetylcholinesterase inhibitors. Although the use of Alzheimer's medications to control symptoms is often only transient, the Alzheimer's disease disease itself may be halted and/or halted for an interval of time. The medication amiloride is used on many of the patients diagnosed with Alzheimer's disease. If the patient is experiencing difficulty in walking, it is beneficial to start with amiloride as the first step in the treatment so that treatment can be applied to the root problem.
The onset of Alzheimer's Disease is thought to result from various combinations of genetic, environmental and lifestyle factors. It is likely that multiple factors play a role in determining the susceptibility to develop AD from one person to the next. Studies evaluating the causes of Alzheimer's Disease are complicated by the many factors that contribute to the prevalence and age of onset of the disease. We are only beginning to unravel the mechanisms that cause Alzheimer syndrome. However, if we aim to discover the causes of Alzheimer's Disease, we must seek evidence from other research that indicates if it is possible. Our current research has focused on the risk factors, including exposure to toxins, drugs, and genetics. More research and observation needs to be done to determine if there is a causal link.
The prevalence of Alzheimer's disease in the UK is estimated at 1 in 68 people aged 65+ years. As this age group continues to grow, the disease burden will be greater with a shift for the disease to become more common.\n
Alzheimer disease can be suspected in the absence of history or specific symptoms in those who do not have other risk factors. As dementia progresses, the cognitive deficits can lead to severe impairment in social functioning and living arrangements.\n
There is a paucity of treatment options for dementia. CBT is the most common therapy that is used to treat individuals with Alzheimer disease. Physical and occupational therapy are also commonly used in conjunction with CBT. There is an urgent need for the development of new therapies for this significant group of people.
The total number of Alzheimer cases per year varies according to the demographic characteristics of the State. The highest number occurs in South Dakota, Iowa, and Mississippi. The lowest number occurs in Hawaii and Washington. Differences in incidence between States can probably be attributed, in large part, to differences in health care and medical care.
Brightgo is a viable, novel approach to cognitive training with the potential benefit to the individual user as well as a new treatment methodology and technology platform. It is intended for use with individuals with MCI and mild dementia and has been trialled in a randomized controlled clinical trial, the CONGO Randomised Controlled Trial of Brightgo Cognitive Training (CONTRORD) for the University of Cambridge. Funding of the study was provided by Cure Alzheimer's Trust and Brightgigo.
There is limited evidence supporting brightcog, and much unpublished data and reports that are not reported in relevant peer-reviewed papers. Brightcog has a weak positive influence on cognition and may improve cognitive skills in patients with mild to moderate Alzheimer's disease. Brightcog has not been shown to change disability or death compared with other DAT treatment regimes. The use of Brightcog in cognitive rehabilitation will only be used once evidence shows that it reduces impairment.
Brightgo training (brain trainer) improved cognitive performance in patients with early Alzheimer disease. Subjects had to learn and retain knowledge of various computerised tasks before being trained on an 'experimenter-guided exercise program'. Brightgo training is safe and does not require daily adherence.
Brightgo does not appear to be safe and lacks evidence for its efficacy within the context of clinical trials to date. Despite this, people may wish to continue to use Brightgo on a volunteer basis. Although patients are advised to notify the prescribing neurologist as soon as these concerns arise or as and when it happens it's imperative that such advice is well communicated and not confusing or misleading. This would include informing patients about the risk of bright light at night and bright light from the sun. Furthermore, due to the high rate of adverse effects, patients should not take any medication to help alleviate any symptoms they may experience as part of their Brightgo treatment.
Brightgo is the first cognitive training approved by the US Food and Drug Administration to improve cognition in patients with mild to moderate AD. Brightgo is also the first training program for patients with mild to moderate AD which provides the most scientifically compelling evidence for its effectiveness.
Based on the data available in the UK the five-year-averaged fatality rates for males with AD were low (2.9%). The low fatality rates in this study of patients with newly diagnosed disease do not support the current UK National Institute for Health and Clinical Excellence guideline, which recommends a minimum five-year survival of 50%; the guideline could, however, be supported by the current consensus paper by the APA, which concluded that in older people the five-year survival rate for non-severe AD is about 80%. The present study did not include patients with mild cognitive impairment.